Roche joining forces to forward precision oncology

Effective implementation of personalised medicine guidelines

Epidemiology data for acute myeloid leukaemia and the ALESE study

Shortening the time to manufacture CAR T-cells

ASPIRE update: Carfilzomib triplet for relapsed / refractory myeloma

Six-month follow up of CTL019 for diffuse large B-cell lymphoma

Anti-BCMA CAR T cell therapy for multiple myeloma

Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial

Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma

ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma

Long term follow up on the ZUMA-1 trial for nHL

BLU-285 for advanced systemic mastocytosis